20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
17 citations
,
May 1998 in “Steroids” Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
September 2010 in “European Urology Supplements” April 2022 in “The Journal of Urology” Men may experience long-term sexual dysfunction after stopping Finasteride.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
January 2011 in “Reactions Weekly”
1054 citations
,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
January 2009 in “Acta urologica Belgica” Finasteride effectively treats BPH by reducing prostate size and improving symptoms.
15 citations
,
September 2014 in “JAMA Dermatology”
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
6 citations
,
November 1998 in “The Journal of Clinical Pharmacology” Finasteride interacts with terazosin, but not doxazosin; caution needed.
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
39 citations
,
January 2012 in “Indian Dermatology Online Journal” Finasteride may cause sexual side effects like erectile dysfunction, but they are reversible and affect less than 2% of men.
March 2026 in “Journal of the American Academy of Dermatology” 5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
May 2015 in “Journal of The American Academy of Dermatology” Young men taking finasteride for hair loss have a higher risk of sexual dysfunction.
January 2003 in “Humana Press eBooks” Dihydrotestosterone and 5α-Reductase play a role in hair loss and prostate health, and finasteride can increase hair growth in men without affecting sperm production, but it doesn't work for postmenopausal women with hair loss.
3 citations
,
June 1996 in “PubMed” Finasteride may help reduce male hair loss and excessive hair growth by lowering DHT levels.
April 2007 in “The Journal of Urology” Finasteride reduces bleeding risk during prostate surgery.
May 2024 in “Reactions weekly” January 2009 in “The Hastings Center Report” Finasteride reduces prostate cancer risk but may increase high-grade cancer risk.
August 1986 in “Lung India” Finasteride effectively prevents hair loss and promotes hair growth in men with androgenetic alopecia.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
November 2013 in “Annales de Dermatologie et de Vénéréologie”